Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
在12岁及以上囊性纤维化患者中,Vanzacaftor-tezacaftor-deutivacaftor 与 elexacaftor-tezacaftor-ivacaftor 的疗效比较(SKYLINE 试验 VX20-121-102 和 VX20-121-103):两项随机、活性对照、3期试验的结果
期刊:Lancet Respiratory Medicine
影响因子:32.8
doi:10.1016/S2213-2600(24)00411-9
Keating, Claire; Yonker, Lael M; Vermeulen, François; Prais, Dario; Linnemann, Rachel W; Trimble, Aaron; Kotsimbos, Tom; Mermis, Joel; Braun, Andrew T; O'Carroll, Mark; Sutharsan, Sivagurunathan; Ramsey, Bonnie; Mall, Marcus A; Taylor-Cousar, Jennifer L; McKone, Edward F; Tullis, Elizabeth; Floreth, Tim; Michelson, Peter; Sosnay, Patrick R; Nair, Nitin; Zahigian, Rachel; Martin, Hannah; Ahluwalia, Neil; Lam, Anna; Horsley, Alexander